Literature DB >> 35833912

Pathogenic autoantibodies to IFN-γ act through the impedance of receptor assembly and Fc-mediated response.

Han-Po Shih1, Jing-Ya Ding1, Junel Sotolongo Bellón2, Yu-Fang Lo1, Pei-Han Chung3, He-Ting Ting1, Jhan-Jie Peng1, Tsai-Yi Wu1, Chia-Hao Lin1, Chia-Chi Lo1, You-Ning Lin1, Chun-Fu Yeh1,4, Jiun-Bo Chen5, Ting-Shu Wu4,6, Yuag-Meng Liu7, Chen-Yen Kuo1,8, Shang-Yu Wang1,9, Kun-Hua Tu1,6,10, Chau Yee Ng1,11, Wei-Te Lei1,12, Yu-Huan Tsai13, Jou-Han Chen5, Ya-Ting Chuang14, Jing-Yi Huang3, Félix A Rey15, Hung-Kai Chen3, Tse-Wen Chang5, Jacob Piehler2, Chih-Yu Chi16,17, Cheng-Lung Ku1,18,19.   

Abstract

Anti-interferon (IFN)-γ autoantibodies (AIGAs) are a pathogenic factor in late-onset immunodeficiency with disseminated mycobacterial and other opportunistic infections. AIGAs block IFN-γ function, but their effects on IFN-γ signaling are unknown. Using a single-cell capture method, we isolated 19 IFN-γ-reactive monoclonal antibodies (mAbs) from patients with AIGAs. All displayed high-affinity (KD < 10-9 M) binding to IFN-γ, but only eight neutralized IFN-γ-STAT1 signaling and HLA-DR expression. Signal blockade and binding affinity were correlated and attributed to somatic hypermutations. Cross-competition assays identified three nonoverlapping binding sites (I-III) for AIGAs on IFN-γ. We found that site I mAb neutralized IFN-γ by blocking its binding to IFN-γR1. Site II and III mAbs bound the receptor-bound IFN-γ on the cell surface, abolishing IFN-γR1-IFN-γR2 heterodimerization and preventing downstream signaling. Site III mAbs mediated antibody-dependent cellular cytotoxicity, probably through antibody-IFN-γ complexes on cells. Pathogenic AIGAs underlie mycobacterial infections by the dual blockade of IFN-γ signaling and by eliminating IFN-γ-responsive cells.
© 2022 Shih et al.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35833912      PMCID: PMC9287643          DOI: 10.1084/jem.20212126

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   17.579


  70 in total

1.  Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2005-12-02       Impact factor: 47.728

2.  Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations.

Authors:  Guillaume Vogt; Ariane Chapgier; Kun Yang; Nadia Chuzhanova; Jacqueline Feinberg; Claire Fieschi; Stéphanie Boisson-Dupuis; Alexandre Alcais; Orchidée Filipe-Santos; Jacinta Bustamante; Ludovic de Beaucoudrey; Ibrahim Al-Mohsen; Sami Al-Hajjar; Abdulaziz Al-Ghonaium; Parisa Adimi; Mehdi Mirsaeidi; Soheila Khalilzadeh; Sergio Rosenzweig; Oscar de la Calle Martin; Thomas R Bauer; Jennifer M Puck; Hans D Ochs; Dieter Furthner; Carolin Engelhorn; Bernd Belohradsky; Davood Mansouri; Steven M Holland; Robert D Schreiber; Laurent Abel; David N Cooper; Claire Soudais; Jean-Laurent Casanova
Journal:  Nat Genet       Date:  2005-05-29       Impact factor: 38.330

3.  Autoreactivity in human IgG+ memory B cells.

Authors:  Thomas Tiller; Makoto Tsuiji; Sergey Yurasov; Klara Velinzon; Michel C Nussenzweig; Hedda Wardemann
Journal:  Immunity       Date:  2007-02       Impact factor: 31.745

4.  Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin.

Authors:  M A O'Donnell; Y Luo; X Chen; A Szilvasi; S E Hunter; S K Clinton
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

5.  Identification of a major epitope by anti-interferon-γ autoantibodies in patients with mycobacterial disease.

Authors:  Chia-Hao Lin; Chih-Yu Chi; Han-Po Shih; Jing-Ya Ding; Chia-Chi Lo; Shang-Yu Wang; Chen-Yen Kuo; Chun-Fu Yeh; Kun-Hua Tu; Shou-Hsuan Liu; Hung-Kai Chen; Chen-Hsuan Ho; Mao-Wang Ho; Chen-Hsiang Lee; Hsin-Chin Lai; Cheng-Lung Ku
Journal:  Nat Med       Date:  2016-08-15       Impact factor: 53.440

6.  Adult-onset immunodeficiency in Thailand and Taiwan.

Authors:  Sarah K Browne; Peter D Burbelo; Ploenchan Chetchotisakd; Yupin Suputtamongkol; Sasisopin Kiertiburanakul; Pamela A Shaw; Jennifer L Kirk; Kamonwan Jutivorakool; Rifat Zaman; Li Ding; Amy P Hsu; Smita Y Patel; Kenneth N Olivier; Viraphong Lulitanond; Piroon Mootsikapun; Siriluck Anunnatsiri; Nasikarn Angkasekwinai; Boonmee Sathapatayavongs; Po-Ren Hsueh; Chi-Chang Shieh; Margaret R Brown; Wanna Thongnoppakhun; Reginald Claypool; Elizabeth P Sampaio; Charin Thepthai; Duangdao Waywa; Camilla Dacombe; Yona Reizes; Adrian M Zelazny; Paul Saleeb; Lindsey B Rosen; Allen Mo; Michael Iadarola; Steven M Holland
Journal:  N Engl J Med       Date:  2012-08-23       Impact factor: 91.245

7.  Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets.

Authors:  E A Bach; S J Szabo; A S Dighe; A Ashkenazi; M Aguet; K M Murphy; R D Schreiber
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

8.  Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma.

Authors:  Beate Kampmann; Cheryl Hemingway; Alick Stephens; Robert Davidson; Anna Goodsall; Suzanne Anderson; Mark Nicol; Elisabeth Schölvinck; David Relman; Simon Waddell; Paul Langford; Brian Sheehan; Lynn Semple; Katalin A Wilkinson; Robert J Wilkinson; Stanley Ress; Martin Hibberd; Michael Levin
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

9.  Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections.

Authors:  Jing Guo; Xin-Qiang Ning; Jing-Ya Ding; Yan-Qing Zheng; Na-Na Shi; Feng-Yao Wu; You-Kun Lin; Han-Po Shih; He-Ting Ting; Gang Liang; Xiang-Chan Lu; Jin-Ling Kong; Ke Wang; Yi-Bo Lu; Yu-Jiao Fu; Rong Hu; Tian-Min Li; Kai-Su Pan; Xiu-Ying Li; Chun-Yang Huang; Yu-Fang Lo; Ian Yi-Feng Chang; Chun-Fu Yeh; Kun-Hua Tu; Yu-Huan Tsai; Cheng-Lung Ku; Cun-Wei Cao
Journal:  J Exp Med       Date:  2020-12-07       Impact factor: 14.307

Review 10.  Autoantibodies against cytokines: phenocopies of primary immunodeficiencies?

Authors:  Chen-Lung Ku; Chih-Yu Chi; Horst von Bernuth; Rainer Doffinger
Journal:  Hum Genet       Date:  2020-05-17       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.